What is the current valuation of the South America point-of-care molecular diagnostics market?

The market valuation was $312.39 Million in 2024. Read More

What is the projected market size for the South America point-of-care molecular diagnostics market by 2035?

The projected valuation for 2035 is $645.4 Million. Read More

What are the main types of tests contributing to the market, and what were their valuations in 2024?

In 2024, PCR Tests were valued at $160.0 Million, Nucleic Acid Amplification Tests at $140.0 Million, Microarray at $100.0 Million, Next-Generation Sequencing at $120.0 Million, and Other Genetic Tests at $125.4 Million. Read More

What applications are driving the South America point-of-care molecular diagnostics market?

In 2024, Infectious Diseases accounted for $200.0 Million, Genetic Testing for $150.0 Million, Cancer Diagnosis for $120.0 Million, and Metabolic Disorders for $75.4 Million. Read More

What end-use segments are prominent in the South America point-of-care molecular diagnostics market?

In 2024, Hospitals generated $210.0 Million, Diagnostic Laboratories $160.0 Million, Home Care Settings $100.0 Million, and Outpatient Clinics $175.4 Million. Read More

How does the market growth in South America compare to other regions?

While specific comparisons are not provided, the projected growth rate of 6.82% during 2025 - 2035 suggests a robust expansion in the South America market. Read More

What factors are likely to influence the growth of the South America point-of-care molecular diagnostics market?

Factors may include advancements in technology, increasing demand for rapid diagnostics, and the growing prevalence of infectious diseases and genetic disorders. Read More

South America Point of Care Molecular Diagnostics Market

Q: What is the expected CAGR for the South America point-of-care molecular diagnostics market during the forecast period 2025 - 2035?

The expected CAGR is 6.82% during the forecast period. Read More

Q: Which companies are the key players in the South America point-of-care molecular diagnostics market?

Key players include Abbott Laboratories, Roche Diagnostics, Cepheid, Thermo Fisher Scientific, Hologic, Inc., Qiagen N.V., BD, and GenMark Diagnostics. Read More

Q: What technologies are utilized in the South America point-of-care molecular diagnostics market, and what were their valuations in 2024?

In 2024, Polymerase Chain Reaction was valued at $250.0 Million, Isothermal Amplification at $100.0 Million, Sanger Sequencing at $150.0 Million, and CRISPR Technology at $145.4 Million. Read More

ID: MRFR/MED/49961-HCR

200 Pages

Rahul Gotadki

Last Updated: February 06, 2026

South America Point-of-care Molecular Diagnostics Market Research Report: Size, Share, Trend Analysis By Product Type (PCR Tests, Nucleic Acid Amplification Tests, Microarray, Next-Generation Sequencing, Other Genetic Tests), By Applications (Infectious Diseases, Genetic Testing, Cancer Diagnosis, Metabolic Disorders), By End-use (Hospitals, Diagnostic Laboratories, Home Care Settings, Outpatient Clinics), By Technology (Isothermal Amplification, Polymerase Chain Reaction, Sanger Sequencing, CRISPR Technology), and By Regional (Brazil, Mexico, Argentina, Rest of South America) - Growth Outlook & Industry Forecast 2025 To 2035

South America Point of Care Molecular Diagnostics Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)6.82%

2024 Market Size$ 312.39 Million

2025 Market Size$ 333.69 Million

2035 Market Size$ 645.4 Million

Key Players

Abbott Laboratories

Roche Diagnostics

Cepheid

Thermo Fisher Scientific

Hologic

Inc.

Trends

Technological Advancements
Regulatory Support
Increased Demand for Rapid Testing

Opportunities

Rising Prevalence of Infectious Diseases
Growing Awareness of Personalized Medicine
Rising Demand for Home Healthcare Solutions

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Life Sciences, BY Type (USD Million)
  1. 4.1.1 PCR Tests
  2. 4.1.2 Nucleic Acid Amplification Tests
  3. 4.1.3 Microarray
  4. 4.1.4 Next-Generation Sequencing
  5. 4.1.5 Other Genetic Tests
2. 4.2 Life Sciences, BY Application (USD Million)
  1. 4.2.1 Infectious Diseases
  2. 4.2.2 Genetic Testing
  3. 4.2.3 Cancer Diagnosis
  4. 4.2.4 Metabolic Disorders
3. 4.3 Life Sciences, BY End Use (USD Million)
  1. 4.3.1 Hospitals
  2. 4.3.2 Diagnostic Laboratories
  3. 4.3.3 Home Care Settings
  4. 4.3.4 Outpatient Clinics
4. 4.4 Life Sciences, BY Technology (USD Million)
  1. 4.4.1 Isothermal Amplification
  2. 4.4.2 Polymerase Chain Reaction
  3. 4.4.3 Sanger Sequencing
  4. 4.4.4 CRISPR Technology
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Life Sciences
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Life Sciences
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Abbott Laboratories (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Roche Diagnostics (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Cepheid (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Thermo Fisher Scientific (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Hologic, Inc. (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Qiagen N.V. (NL)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 BD (Becton, Dickinson and Company) (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 GenMark Diagnostics (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 SOUTH AMERICA MARKET ANALYSIS BY TYPE
3. 6.3 SOUTH AMERICA MARKET ANALYSIS BY APPLICATION
4. 6.4 SOUTH AMERICA MARKET ANALYSIS BY END USE
5. 6.5 SOUTH AMERICA MARKET ANALYSIS BY TECHNOLOGY
6. 6.6 KEY BUYING CRITERIA OF LIFE SCIENCES
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF LIFE SCIENCES
9. 6.9 DRIVERS IMPACT ANALYSIS: LIFE SCIENCES
10. 6.10 RESTRAINTS IMPACT ANALYSIS: LIFE SCIENCES
11. 6.11 SUPPLY / VALUE CHAIN: LIFE SCIENCES
12. 6.12 LIFE SCIENCES, BY TYPE, 2024 (% SHARE)
13. 6.13 LIFE SCIENCES, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 LIFE SCIENCES, BY APPLICATION, 2024 (% SHARE)
15. 6.15 LIFE SCIENCES, BY APPLICATION, 2024 TO 2035 (USD Million)
16. 6.16 LIFE SCIENCES, BY END USE, 2024 (% SHARE)
17. 6.17 LIFE SCIENCES, BY END USE, 2024 TO 2035 (USD Million)
18. 6.18 LIFE SCIENCES, BY TECHNOLOGY, 2024 (% SHARE)
19. 6.19 LIFE SCIENCES, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 South America MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY APPLICATION, 2025-2035 (USD Million)
  3. 7.2.3 BY END USE, 2025-2035 (USD Million)
  4. 7.2.4 BY TECHNOLOGY, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

South America Life Sciences Market Segmentation

Life Sciences By Type (USD Million, 2025-2035)

PCR Tests
Nucleic Acid Amplification Tests
Microarray
Next-Generation Sequencing
Other Genetic Tests

Life Sciences By Application (USD Million, 2025-2035)

Infectious Diseases
Genetic Testing
Cancer Diagnosis
Metabolic Disorders

Life Sciences By End Use (USD Million, 2025-2035)

Hospitals
Diagnostic Laboratories
Home Care Settings
Outpatient Clinics

Life Sciences By Technology (USD Million, 2025-2035)

Isothermal Amplification
Polymerase Chain Reaction
Sanger Sequencing
CRISPR Technology

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”